

Amendments to the Claims

1-141. (Canceled)

142. (Currently Amended) An isolated antibody comprising a VH CDR1 ~~having~~ comprising the amino acid sequence of SEQ ID NO:26, a VH CDR2 ~~having~~ comprising the amino acid sequence of SEQ ID NO:2, a VH CDR3 ~~having~~ comprising the amino acid sequence of SEQ ID NO:3, a VL CDR1 ~~having~~ comprising the amino acid sequence of SEQ ID NO:62, a VL CDR2 ~~having~~ comprising the amino acid sequence of SEQ ID NO:65, and a VL CDR3 ~~having~~ comprising the amino acid sequence of SEQ ID NO:20.

143-153. (Canceled)

154. (Previously Presented) An isolated antibody which is encoded by the vector deposited as ATCC deposit No. PTA-5913.

155. (Canceled)

156. (Currently Amended) ~~The isolated~~ An antibody conjugate comprising:

the antibody of claim 142 or 154, ~~wherein the antibody is~~ conjugated to a detectable substance.

157. (Previously Presented) A pharmaceutical composition comprising the antibody of claim 142 or 154 and a pharmaceutically acceptable carrier or excipient.

158. (Previously Presented) The pharmaceutical composition of claim 157 formulated for pulmonary, intranasal, oral, subcutaneous, intradermal or parental administration.

159. (Previously Presented) The pharmaceutical composition of claim 157 formulated for sustained release formulation.

160. (Previously Presented) A lyophilized formulation comprising the antibody of claim 142 or 154.

161. (Previously Presented) A liquid formulation comprising the antibody of claim 142 or 154.

162. (Previously Presented) A kit comprising the antibody of claim 142 or 154, in one or more containers, and instructions for use.

163-168. (Canceled)